基于系统药理学方法探讨散风通窍滴丸治疗过敏性鼻炎的作用靶点及机制

孙淑娴; 顾晓群; 钱佩瑶; 余雪瑞; 郑劼; 赵倩; 李佳禹; 洪敏

doi:10.14148/j.issn.1672-0482.2023.0999

基于系统药理学方法探讨散风通窍滴丸治疗过敏性鼻炎的作用靶点及机制

doi: 10.14148/j.issn.1672-0482.2023.0999

孙淑娴^{1, 2,},
顾晓群^{1, 2},
钱佩瑶^{1, 2},
余雪瑞^{1, 2},
郑劼^{1, 2, 3},
赵倩²,
李佳禹²,
洪敏^{1, 2, ,}

1.
南京中医药大学药学院, 江苏省中药药效与安全性评价重点实验室, 江苏南京 210023
2.
扬子江药业集团, 江苏泰州 225321
3.
南京中医药大学医学院·整合医学院, 江苏南京 210023

基金项目:

江苏省中药药效与安全性评价重点实验室和扬子江药业集团联合资助项目 JKLPSE202002

详细信息

作者简介:
孙淑娴，女，硕士研究生，E-mail: 382898408@qq.com

通讯作者:
洪敏, 女, 教授, 博士生导师, 主要从事中药药理学研究, E-mail: minhong@njucm.edu.cn

中图分类号: R285.5
计量
- 文章访问数: 190
- HTML全文浏览量: 19
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2023-01-19
- 网络出版日期: 2023-11-10
- 发布日期: 2023-10-10

Exploring the Target and Mechanism of Sanfeng Tongqiao Dropping Pills in the Treatment of Allergic Rhinitis Based on Systematic Pharmacological Methods

SUN Shu-xian^{1, 2
,},
GU Xiao-qun^{1, 2},
QIAN Pei-yao^{1, 2},
YU Xue-rui^{1, 2},
ZHENG Jie^{1, 2, 3},
ZHAO Qian²,
LI Jia-yu²,
HONG Min^{1, 2
, ,}

1.
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
2.
Yangtze River Pharmaceutical Group, Taizhou 225321, China
3.
School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

摘要

摘要: 目的运用网络药理学研究方法筛选散风通窍滴丸(SFTQ)活性成分, 探讨其治疗过敏性鼻炎(Allergic rhinitis, AR)的靶点和作用机制。方法利用中药系统药理学分析平台(TCMSP)筛选SFTQ的活性成分和作用靶点。运用TCMSP和TTD数据库筛选AR相关治疗靶点。通过Cytoscape构建SFTQ活性成分-AR疾病靶点网络, 预测潜在靶点。采用Davidv 6.8数据库对核心靶点进行KEGG通路富集分析。建立AR小鼠模型, 用不同剂量的SFTQ进行激发期干预, 通过行为学、病理切片HE染色、外周血EOS、IgE水平及颈部淋巴结中ILC2数量等指标进行评价。结果筛选出42个活性成分, 16个潜在靶点。KEGG富集分析得到18条潜在信号通路, 主要涉及T细胞受体信号通路、HIF-1信号通路等。体内实验表明, SFTQ能显著减少AR小鼠喷嚏和挠鼻次数, 减轻黏膜增厚程度, 减少外周血中EOS, 降低血清中IgE水平, 同时能显著减少颈部淋巴结中ILC2的数量。结论运用系统药理学方法, 揭示了SFTQ治疗AR的多成分、多靶点、多通路的特点, 为SFTQ的机制研究提供了可能的靶点和有效成分, 为更全面地认识及应用该方奠定了基础。
- 过敏性鼻炎 /
- 散风通窍滴丸 /
- 网络药理学 /
- 靶点预测
Abstract: OBJECTIVE To screen the active components of Sanfeng Tongqiao (SFTQ) by using network pharmacological method and to investigate the target and mechanism of SFTQ in the treatment of allergic rhinitis (AR). METHODS The active components and targets of SFTQ were screened by TCMSP. TCMSP and TTD database were used to screen AR-related therapeutic targets. SFTQ active components-AR target network was constructed by Cytoscape to predict potential targets. KEGG pathway enrichment analysis was performed on Davidv 6.8 database. An AR mouse model was established, and different doses of SFTQ were used for intervention during the stimulation period. The results were evaluated through behavioral indicators, pathological sections, HE staining, peripheral blood EOS and IgE levels, and the number of ILC2 in cervical lymph nodes. RESULTS 42 active components and 16 potential targets were identified. KEGG enrichment analysis revealed 18 potential signaling pathways involving T cell receptor signaling pathway, HIF-1 signaling pathway, etc. In vivo, SFTQ significantly reduced the frequency of sneezing and rubbing, the degree of mucosal thickening, peripheral blood EOS, IgE level and the amount of ILC2 in cervical lymph nodes. CONCLUSION Using systems pharmacology methods, the study revealed the multi-component, multi-target, and multi-pathway characteristics of SFTQ in treating AR, providing possible targets and active components for the mechanism study of SFTQ, and laying the foundation for a more comprehensive understanding and application of this prescription.
- allergic rhinitis /
- Sanfeng Tongqiao dropping pills /
- network pharmacology /
- target prediction

HTML全文

图 1 SFTQ组成药味-活性成分网络

注：粉色菱形代表药物, 紫色圆形代表活性成分

Figure 1. SFTQ composition medicine flavor-active component network

下载: 全尺寸图片幻灯片

图 2 SFTQ活性成分对应作用靶点网络图

注：紫色圆形代表活性成分, 黄色三角代表靶点

Figure 2. Network diagram of corresponding action targets of SFTQ active components

下载: 全尺寸图片幻灯片

图 3 活性成分-疾病靶点网络图

注：紫色圆形代表活性成分, 黄色三角代表靶点

Figure 3. Active component-disease target network diagram

下载: 全尺寸图片幻灯片

图 4 SFTQ治疗AR的KEGG pathway分析

Figure 4. KEGG pathway analysis of SFTQ treatment for AR

下载: 全尺寸图片幻灯片

图 5 SFTQ对鼻部症状评分的影响

注：在第25天滴鼻后的20 min内, 对小鼠挠鼻和打喷嚏的次数进行统计(n=12)。与模型组相比, ^*P＜0.05，^***P＜0.001。

Figure 5. The impact of SFTQ on nasal symptom scores

下载: 全尺寸图片幻灯片

图 6 鼻组织HE染色

注：红色箭头指向增厚的鼻黏膜。n=6, ×200。

Figure 6. HE staining of nasal tissue

下载: 全尺寸图片幻灯片

图 7 各组外周血EOS和血清IgE的水平比较

注：与模型组相比, ^*P＜0.05，^***P＜0.001。x±s, n=12。

Figure 7. Comparison of peripheral blood EOS and serum IgE levels in each group

下载: 全尺寸图片幻灯片

图 8 流式细胞术检测颈部淋巴结中ILC2的数量

注：A.圈门逻辑；B.ILC2的数量统计。与模型组相比, ^*P＜0.05。x±s，n=6。

Figure 8. Flow cytometry detection of the number of ILC2 in cervical lymph nodes

下载: 全尺寸图片幻灯片

参考文献(20)

[1]	HELLINGS PW, KLIMEK L, CINGI C, et al. Non-allergic rhinitis: Position paper of the European academy of allergy and clinical immunology[J]. Allergy, 2017, 72(11): 1657-1665. doi: 10.1111/all.13200
[2]	GREINER AN, HELLINGS PW, ROTIROTI G, et al. Allergic rhinitis[J]. Lancet, 2011, 378(9809): 2112-2122. doi: 10.1016/S0140-6736(11)60130-X
[3]	刘静. 基于整体观念变应性鼻炎的中医辨证论治[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 28-30. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYU201703007.htm LIU J. Treatment of allergic rhinitis using syndrome differentiation based on the concept of "holism"in TCM[J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(3): 28-30. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYU201703007.htm
[4]	谢铮. 黄芩汤提取物加减滴鼻液对实验性变应性鼻炎豚鼠模型的影响[D]. 北京: 北京中医药大学, 2010. XIE Z. Effect of Huangqin Decoction extract on Guinea pig model of experimental allergic rhinitis[D]. Beijing: Beijing University of Chinese Medicine, 2010.
[5]	于萍, 刘东. 治疗过敏性鼻炎验方[J]. 中国民间疗法, 2018, 26(14): 5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMJL201814004.htm YU P, LIU D. Prescription for treating allergic rhinitis[J]. China's Naturopathy, 2018, 26(14): 5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMJL201814004.htm
[6]	张翠新, 王庆国. 王庆国教授治疗过敏性鼻炎经验总结[J]. 中国医药导报, 2019, 16(18): 125-128, 132. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201918032.htm ZHANG CX, WANG QG. Professor Wang Qingguo' s experience in the treatment of allergic rhinitis[J]. China Med Her, 2019, 16(18): 125-128, 132. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201918032.htm
[7]	WANG C, REN Q, CHEN XT, et al. System pharmacology-based strategy to decode the synergistic mechanism of Zhi-Zhu Wan for functional dyspepsia[J]. Front Pharmacol, 2018, 9: 841. doi: 10.3389/fphar.2018.00841
[8]	ALAM S, KHAN F. QSAR, docking, ADMET, and system pharmacology studies on tormentic acid derivatives for anticancer activity[J]. J Biomol Struct Dyn, 2018, 36(9): 2373-2390. doi: 10.1080/07391102.2017.1355846
[9]	RU JL, LI P, WANG JN, et al. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6: 13. doi: 10.1186/1758-2946-6-13
[10]	XU X, ZHANG WX, HUANG C, et al. A novel chemometric method for the prediction of human oral bioavailability[J]. Int J Mol Sci, 2012, 13(6): 6964-6982. doi: 10.3390/ijms13066964
[11]	WANG YH, LI Y, DING J, et al. Prediction of binding affinity for estrogen receptor alpha modulators using statistical learning approaches[J]. Mol Divers, 2008, 12(2): 93-102. doi: 10.1007/s11030-008-9080-1
[12]	YAMANISHI Y, KOTERA M, KANEHISA M, et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework[J]. Bioinformatics, 2010, 26(12): i246-i254. doi: 10.1093/bioinformatics/btq176
[13]	LIPINSKI CA, LOMBARDO F, DOMINY BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1[J]. Adv Drug Deliv Rev, 2001, 46(1/2/3): 3-26.
[14]	GILL AL, VERDONK M, BOYLE RG, et al. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development[J]. Curr Top Med Chem, 2007, 7(14): 1408-1422. doi: 10.2174/156802607781696819
[15]	YU H, CHEN JX, XU X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data[J]. PLoS ONE, 2012, 7(5): e37608. doi: 10.1371/journal.pone.0037608
[16]	SONG WJ, NI SL, FU YL, et al. Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: A network pharmacology study[J]. Sci Rep, 2018, 8(1): 17362. doi: 10.1038/s41598-018-35791-9
[17]	JIA ZR, WANG XT, WANG XY, et al. Calycosin alleviates allergic contact dermatitis by repairing epithelial tight junctions via down-regulating HIF-1α[J]. J Cell Mol Med, 2018, 22(9): 4507-4521. doi: 10.1111/jcmm.13763
[18]	张春辉, 邢雪琨, 张慧. 黄芩的药理作用研究[J]. 中兽医医药杂志, 2020, 39(2): 98-100. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZZ202002034.htm ZHANG CH, XING XK, ZHANG H. Pharmacological effects of Radix scutellariae[J]. J Tradit Chin Vet Med, 2020, 39(2): 98-100. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZZ202002034.htm
[19]	任晗堃, 刘宇红, 孟宏, 等. 荆芥复方提取液的抗敏功效研究[J]. 轻工学报, 2016, 31(4): 44-48. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZQB201604007.htm REN HK, LIU YH, MENG H, et al. Study on anti-allergy efficacy of Nepeta cataria prescriptions[J]. J Light Ind, 2016, 31(4): 44-48. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZQB201604007.htm
[20]	HALIM TYF, HWANG YY, SCANLON ST, et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses[J]. Nat Immunol, 2016, 17(1): 57-64.